Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 19, 2007
Twice a day may be better than once a week.
Analysis of: Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Dosing frequency is a small part of the success mix.
March 19, 2007
Metformin should be in the PCOS mix.
Analysis of: Standard Therapy More Effective Than Diabetes Drug In Helping Women With PCOS Achieve Pregnancy | www.medicalnewstoday.com
Author: GLG Expert Contributor
Metformin should be in the PCOS mix.
March 19, 2007
Another me-too drug?
Analysis of: Novartis committed to making Galvus(R) available for patients with type 2 diabetes after US regulators issue ''approvable letter'' | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus must show something special to be embraced.
March 19, 2007
Newer is better?
Analysis of: Novartis' New Blood Pressure Weapon | biz.yahoo.com
Author: GLG Expert Contributor
We need to think twice before approving medications without well-characterized outcomes.
March 19, 2007
Inhaled insulin is over-inflated
Analysis of: Frost & Sullivan Acknowledges MannKind’s Path-breaking Solution to Treat Diabetes | /www.frost.com/prod/servlet/press-release.pag?docid=93822443
Author: GLG Expert Contributor
Inhaled insulin should be prescribed to the truly needle phobic, of which there are few and far between.      
March 19, 2007
More bells, less to ring about
Analysis of: Lilly Introduces World's First Digital Insulin Pen With Memory | www.medicalnewstoday.com
Author: GLG Expert Contributor
The Lilly Pen is high on technology, low on what patients need.
March 19, 2007
Mind/Body Connection
Analysis of: Together Diabetes And Depression Increase Risk To Heart Patients | www.medicalnewstoday.com
Author: GLG Expert Contributor
The mind cannot only heal, it can cause infirmity. Heal the mind, the body will follow.
Carlos DujovneFebruary 12, 2007
Drugs Effects on HDL Cholesterol Levels and Regression of Coronary Atherosclerosis
Analysis of: Effect of very high-intensity Statin therapy on regression of Coronary Atherosclerosis.Nissen S.E. etal | www.jama.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
1.This study's results are the first clinical confirmation of the benefits of a single drug to reverse coronary deposits of cholesterol in patients after just 2 years of treatment with Rosuvastatin (Crestor). 2. These results originated further clinical trials which will be presented at the forthcoming...
January 30, 2007
Missing Lessons in Torcetrapib Paradox
Analysis of: Torcetrapib tanks, but there is still a future in HDL cholesterol-raising therapies | www.theheart.org
Author: GLG Expert Contributor
The surrogate atherosclerosis end point studies with torcetrapib promise to give important, but likely complex clues regarding its paradoxical increase in CVD events and mortality. Some promising HDL-raising approaches still appear to be eluding pharmaceutical R&D.Niacin promises to be a big winner...
January 26, 2007
When will we stop underprescribing niacin for atheroprevention?
Analysis of: An Old Cholesterol Remedy Is New Again | www.nytimes.com
Author: GLG Expert Contributor
With the demise of the clinical development of Torcetrapib we are forced to reevaluate our views of HDL raising.We have had good HDL-raising drugs for many years, but they have gone underutilized and underappreciated.Many cardiologists (often supposed by others to be lipid experts) have never or rarely...

Previous Page : 1 2 3 4 5 6 7 8 981 to 90 of 90

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747